S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
What's Driving Tesla Lower Ahead of its Earnings?
3 Steel Stocks Could Soar on New China Tariffs
How major US stock indexes fared Thursday, 4/18/2024
These are the Top 4 Stocks for Buybacks in 2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
What's Driving Tesla Lower Ahead of its Earnings?
3 Steel Stocks Could Soar on New China Tariffs
How major US stock indexes fared Thursday, 4/18/2024
These are the Top 4 Stocks for Buybacks in 2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
What's Driving Tesla Lower Ahead of its Earnings?
3 Steel Stocks Could Soar on New China Tariffs
How major US stock indexes fared Thursday, 4/18/2024
These are the Top 4 Stocks for Buybacks in 2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
What's Driving Tesla Lower Ahead of its Earnings?
3 Steel Stocks Could Soar on New China Tariffs
How major US stock indexes fared Thursday, 4/18/2024
These are the Top 4 Stocks for Buybacks in 2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
H-CYTE, Inc. stock logo
HCYTD
H-CYTE
$2.02
-49.5%
$2.02
$2.02
$77.00
$521K1.12103 shs400 shs
Hypertension Diagnostics, Inc. stock logo
HDII
Hypertension Diagnostics
$0.00
$0.00
$0.00
$0.00
N/A-2.354,409 shsN/A
Presbia PLC stock logo
LENSF
Presbia
$0.02
$0.02
$0.00
$0.19
$257K5.915,650 shsN/A
QTXB
QuantRx Biomedical
$0.00
$0.00
$0.00
$0.01
$315K-2.13N/AN/A
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
H-CYTE, Inc. stock logo
HCYTD
H-CYTE
0.00%0.00%0.00%0.00%0.00%
Hypertension Diagnostics, Inc. stock logo
HDII
Hypertension Diagnostics
0.00%0.00%-80.00%-80.00%-94.44%
Presbia PLC stock logo
LENSF
Presbia
0.00%0.00%0.00%0.00%0.00%
QTXB
QuantRx Biomedical
0.00%0.00%0.00%-18.37%-20.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
H-CYTE, Inc. stock logo
HCYTD
H-CYTE
N/AN/AN/AN/AN/AN/AN/AN/A
Hypertension Diagnostics, Inc. stock logo
HDII
Hypertension Diagnostics
N/AN/AN/AN/AN/AN/AN/AN/A
Presbia PLC stock logo
LENSF
Presbia
N/AN/AN/AN/AN/AN/AN/AN/A
QTXB
QuantRx Biomedical
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
H-CYTE, Inc. stock logo
HCYTD
H-CYTE
N/AN/AN/AN/A
Hypertension Diagnostics, Inc. stock logo
HDII
Hypertension Diagnostics
N/AN/AN/AN/A
Presbia PLC stock logo
LENSF
Presbia
N/AN/AN/AN/A
QTXB
QuantRx Biomedical
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
H-CYTE, Inc. stock logo
HCYTD
H-CYTE
$1.61M0.32N/AN/A($31.45) per share-0.06
Hypertension Diagnostics, Inc. stock logo
HDII
Hypertension Diagnostics
N/AN/AN/AN/AN/AN/A
Presbia PLC stock logo
LENSF
Presbia
N/AN/AN/AN/AN/AN/A
QTXB
QuantRx Biomedical
N/AN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
H-CYTE, Inc. stock logo
HCYTD
H-CYTE
-$4.80MN/A0.00N/A-450.40%N/A-777.68%N/A
Hypertension Diagnostics, Inc. stock logo
HDII
Hypertension Diagnostics
N/AN/A0.00N/AN/AN/AN/AN/A
Presbia PLC stock logo
LENSF
Presbia
N/AN/A0.00N/AN/AN/AN/AN/A
QTXB
QuantRx Biomedical
-$260KN/A0.00N/AN/AN/AN/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
H-CYTE, Inc. stock logo
HCYTD
H-CYTE
N/AN/AN/AN/AN/A
Hypertension Diagnostics, Inc. stock logo
HDII
Hypertension Diagnostics
N/AN/AN/AN/AN/A
Presbia PLC stock logo
LENSF
Presbia
N/AN/AN/AN/AN/A
QTXB
QuantRx Biomedical
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
H-CYTE, Inc. stock logo
HCYTD
H-CYTE
N/A
0.12
0.12
Hypertension Diagnostics, Inc. stock logo
HDII
Hypertension Diagnostics
N/AN/AN/A
Presbia PLC stock logo
LENSF
Presbia
N/AN/AN/A
QTXB
QuantRx Biomedical
N/AN/AN/A

Ownership

Institutional Ownership

CompanyInstitutional Ownership
H-CYTE, Inc. stock logo
HCYTD
H-CYTE
N/A
Hypertension Diagnostics, Inc. stock logo
HDII
Hypertension Diagnostics
N/A
Presbia PLC stock logo
LENSF
Presbia
N/A
QTXB
QuantRx Biomedical
N/A

Insider Ownership

CompanyInsider Ownership
H-CYTE, Inc. stock logo
HCYTD
H-CYTE
5.24%
Hypertension Diagnostics, Inc. stock logo
HDII
Hypertension Diagnostics
40.00%
Presbia PLC stock logo
LENSF
Presbia
74.20%
QTXB
QuantRx Biomedical
21.90%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
H-CYTE, Inc. stock logo
HCYTD
H-CYTE
8258,000244,000Not Optionable
Hypertension Diagnostics, Inc. stock logo
HDII
Hypertension Diagnostics
2,017N/AN/ANot Optionable
Presbia PLC stock logo
LENSF
Presbia
2017.12 millionN/ANot Optionable
QTXB
QuantRx Biomedical
N/A78.70 million61.46 millionNot Optionable

HCYTD, HDII, QTXB, and LENSF Headlines

SourceHeadline
Quantrx Biomedical Corp QTXBQuantrx Biomedical Corp QTXB
morningstar.com - April 17 at 10:09 PM
Biomedical Research CentreBiomedical Research Centre
icr.ac.uk - October 21 at 2:17 PM
Nanomedicines and Biomedical EngineeringNanomedicines and Biomedical Engineering
helsinki.fi - October 12 at 8:46 AM
BSc Biomedical Sciences / OverviewBSc Biomedical Sciences / Overview
manchester.ac.uk - October 7 at 5:12 PM
Biomedical engineering articles from across Nature PortfolioBiomedical engineering articles from across Nature Portfolio
nature.com - September 23 at 10:43 PM
The Best Places to Be a Biomedical Engineer: MinneapolisThe Best Places to Be a Biomedical Engineer: Minneapolis
mddionline.com - August 29 at 3:15 PM
Wyoming INBRE Phase 4Wyoming INBRE Phase 4
uwyo.edu - August 11 at 1:16 AM
UMaine receives $11.3 million to support biomedical researchUMaine receives $11.3 million to support biomedical research
wabi.tv - April 1 at 7:18 PM
Biomedical Science (Medical Microbiology) MScBiomedical Science (Medical Microbiology) MSc
qmul.ac.uk - March 21 at 7:12 PM
Jinxiang XiJinxiang Xi
uml.edu - March 16 at 10:06 AM
Causal Inference for Statistics, Social, and Biomedical SciencesCausal Inference for Statistics, Social, and Biomedical Sciences
cambridge.org - March 15 at 1:29 PM
Global Biomedical Tester Market Research Report 2022-2032Global Biomedical Tester Market Research Report 2022-2032
finance.yahoo.com - February 12 at 12:56 PM
Lifecore Biomedical receives non-compliance notice from NasdaqLifecore Biomedical receives non-compliance notice from Nasdaq
seekingalpha.com - January 14 at 12:54 AM
$100 million donation to UF Scripps Biomedical Research Institute in Jupiter$100 million donation to UF Scripps Biomedical Research Institute in Jupiter
palmbeachpost.com - October 15 at 3:25 PM
Biological and Biomedical SciencesBiological and Biomedical Sciences
qmul.ac.uk - October 8 at 7:18 AM
QTXB.PK - | Stock Price & Latest News | ReutersQTXB.PK - | Stock Price & Latest News | Reuters
reuters.com - September 14 at 8:52 PM
Quantrx Biomedical (OTC:QTXB), Earnings Estimates, EPS, and RevenueQuantrx Biomedical (OTC:QTXB), Earnings Estimates, EPS, and Revenue
benzinga.com - July 19 at 11:34 PM
Quantrx Biomedical (OTC:QTXB), Analyst Ratings, Price Targets, PredictionsQuantrx Biomedical (OTC:QTXB), Analyst Ratings, Price Targets, Predictions
benzinga.com - July 19 at 11:34 PM

New MarketBeat Followers Over Time

Company Descriptions

H-CYTE logo

H-CYTE

OTCMKTS:HCYTD
H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.
Hypertension Diagnostics logo

Hypertension Diagnostics

OTCMKTS:HDII
Hypertension Diagnostics, Inc. designs, develops, manufactures, and markets proprietary noninvasive medical devices that detect subtle changes in the elasticity of arteries in the United States and internationally. It offers CVProfilor, which allows a physician to non-invasively assess the elasticity of small and large arteries, of which small artery elasticity is the earliest and sensitive marker of cardiovascular disease. The company offers CVProfilor DO-2020, which provides a patient's arterial elasticity indices used in the assessment for underlying vascular disease; CVProfilor MD-3000 that offers a sensitive and specific guide to the presence of blood vessel disease; and HD/PulseWave CR-2000 research cardiovascular profiling system, which provides researchers and scientists with a non-invasive means to assess arterial elasticity in support of human research in various areas. Its products collect 30 seconds of blood pressure waveform data, perform an analysis of the digitized blood pressure waveforms, and generate a CVProfile report that contains information on blood pressure, heart rate, pulse pressure, body surface area, body mass index, and C1-large and C2-small artery elasticity indices. The company sells its products to primary care physicians, cardiologists, health care professionals, trained medical personnel, research investigators at academic medical research centers, government institutes, cardiovascular specialists, and pharmaceutical firms. It markets its products through a representative organization in the United States. Hypertension Diagnostics, Inc. was founded in 1988 and is based in Richmond Hill, Canada.
Presbia logo

Presbia

OTCMKTS:LENSF
Presbia PLC, an ophthalmic device company, develops and markets optical lens implants for treating presbyopia. The company provides the refractive lens for patient surgeries, as well as accessories for procedures. It primarily operates in the United States, South Korea, Australia, Italy, the Netherlands, Ireland, Canada, and Germany. The company was founded in 2014 and is headquartered in Dublin, Ireland.

QuantRx Biomedical

OTCMKTS:QTXB
QuantRx Biomedical Corporation engages in the development and commercialization of patented miniform pads (PADs) and PAD based over-the-counter products in the United States. It is also developing genomic diagnostics for the laboratory market based on its lateral flow patents, including RapidSense technology, a one-step lateral flow test. The company's PAD products are used for the treatment of hemorrhoids, minor vaginal infection, urinary incontinence, general catamenial uses, and other medical needs. Its products include InSync, a feminine hygienic interlabial pad; Unique miniform, a treated pad for the temporary relief of the itch and discomfort associated with hemorrhoids and minor vaginal infection, as well as an untreated pad for the daily protection of light urinary, vaginal, or anal leakage; and other treated miniform products. QuantRx Biomedical Corporation was incorporated in 1986 and is based in Tualatin, Oregon.